<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253721</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001299</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>1299</secondary_id>
    <secondary_id>ONC-98018-L</secondary_id>
    <secondary_id>4834</secondary_id>
    <nct_id>NCT00253721</nct_id>
  </id_info>
  <brief_title>Melphalan With BBBD in Treating Patients With Brain Malignancies</brief_title>
  <official_title>Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      drugs directly into the arteries around the tumor may kill more tumor cells. Mannitol may&#xD;
      open the blood vessels around the brain [Blood-Brain Barrier Disruption (BBBD)]and allow&#xD;
      melphalan to be carried directly to the brain tumor. Giving melphalan together with BBBD may&#xD;
      be an effective treatment for central nervous system cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying side effects and best dose of melphalan when given&#xD;
      together with mannitol in treating patients with central nervous system cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intra-arterial melphalan when given in&#xD;
           combination with BBBD in patients with primary or metastatic central nervous system&#xD;
           (CNS) malignancy.&#xD;
&#xD;
        -  Determine the toxic effects of melphalan given with BBBD in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of melphalan.&#xD;
&#xD;
      Patients receive intra-arterial mannitol with BBBD followed by intra-arterial melphalan over&#xD;
      10 minutes on days 1 and 2*. Treatment repeats every 4 weeks for up to 12 monthly courses in&#xD;
      the absence of disease progression or unacceptable toxicity .&#xD;
&#xD;
      NOTE: *Patients with gliomas localized to the posterior circulation (i.e., brain stem&#xD;
      gliomas) receive melphalan on day 1 only.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of melphalan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year; every 6&#xD;
      months for the next 2 years; then annually.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Other competing clinical trials affecting enrollment&#xD;
  </why_stopped>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)of Melphalan as measured by NCI common toxicity criteria (CTC) v2 toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>MTD = dose of Melphalan that produces grade 3 neurotoxicity in 33% of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of chemotherapy regimen as measured by clinical and radiographic response from first day of treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>All levels: Every 4 weeks for up to one year&#xD;
Dose Escalation Plan:&#xD;
Level 1: 4mg/m2/day x 2 days&#xD;
Level 2: 6mg/m2/day x 2 days&#xD;
Level 3: 8mg/m2/day x 2 days&#xD;
Level 4: 10mg/m2/day x 2 days&#xD;
Level 5: 12mg/m2/day x 2 days</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Signed written informed consent form in accordance with institutional guidelines&#xD;
&#xD;
          -  Histologically confirmed primary or metastatic CNS malignancy (Patients with&#xD;
             metastatic disease must have histological confirmation of the primary cancer AND&#xD;
             confirmation by surgical specimen, cerebrospinal fluid cytology, elevated tumor&#xD;
             markers, or clinical evidence of CNS involvement)&#xD;
&#xD;
          -  Single or multiple cerebellar or cerebral cortex lesions allowed&#xD;
&#xD;
          -  Life expectancy at least 60 days&#xD;
&#xD;
          -  Radiographically evaluable disease by MRI or CT scan&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy (systemic, cranial, and/or spinal)&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy (42 days for nitrosoureas)&#xD;
&#xD;
          -  Adequate cardiac and pulmonary function to tolerate general anesthesia&#xD;
&#xD;
          -  Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
          -  Other tumor masses in the spinal cord allowed provided there is no radiographic or&#xD;
             clinical evidence of spinal cord block&#xD;
&#xD;
          -  Available for follow-up for at least one year following completion of treatment&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 2 months prior to, during, and&#xD;
             for 3 months after study participation&#xD;
&#xD;
          -  Pre-treatment lab tests within 14 days prior to initiation of treatment:&#xD;
&#xD;
               -  White blood cell count (WBC) &gt; 2,500/mm^3&#xD;
&#xD;
               -  Absolute granulocyte count &gt; 1,200/mm^3&#xD;
&#xD;
               -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
               -  Hematocrit &gt; 30% (transfusion allowed)&#xD;
&#xD;
               -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times ULN&#xD;
&#xD;
               -  Creatinine ≤ 2 times ULN&#xD;
&#xD;
          -  Subjects with history of smoking or emphysema require diffusing capacity of lung for&#xD;
             carbon monoxide (DLCO) ≥ 80% of predicted value for age&#xD;
&#xD;
          -  Histological sections submitted for pathology review&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Radiographic evidence of excessive intra-cranial mass effect and/or spinal block&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to melphalan&#xD;
&#xD;
          -  NCI CTC Grade 3 or greater baseline neurologic symptoms&#xD;
&#xD;
          -  Immunologically compromised (Concurrent corticosteroids for tumor edema allowed)&#xD;
&#xD;
          -  Unable to tolerate general anesthesia&#xD;
&#xD;
          -  Pregnant, positive human chorionic gonadotropin (HCG) test, or lactating&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Receiving concurrent radiotherapy or immunotherapy&#xD;
&#xD;
          -  Serious illness that would preclude study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Neuwelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

